Acrivon Therapeutics IncNASDAQ:ACRV
- LAST PRICE9.8200
- TODAY'S CHANGE (%)0.3100 (3.2597%)
- Bid / Lots9.5000/ 2
- Ask / Lots11.6600/ 3
- Open / Previous Close9.5600 / 9.5100
- Day Range
- 52 Week Range
- Volume320,572
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACRV |
|---|---|---|
| 09:32 ET | 1857 | 9.56 |
| 09:36 ET | 1200 | 9.53 |
| 09:38 ET | 1000 | 9.54 |
| 09:39 ET | 576 | 9.53 |
| 09:41 ET | 400 | 9.47 |
| 09:43 ET | 2582 | 9.55 |
| 09:45 ET | 200 | 9.505 |
| 09:50 ET | 7000 | 9.63 |
| 09:52 ET | 1000 | 9.505 |
| 09:54 ET | 1500 | 9.465 |
| 09:56 ET | 2128 | 9.46 |
| 09:57 ET | 1700 | 9.49 |
| 09:59 ET | 510 | 9.485 |
| 10:01 ET | 100 | 9.35 |
| 10:03 ET | 802 | 9.35 |
| 10:06 ET | 260 | 9.25 |
| 10:08 ET | 600 | 9.4 |
| 10:10 ET | 1000 | 9.25 |
| 10:12 ET | 2498 | 9.4 |
| 10:14 ET | 3800 | 9.495 |
| 10:17 ET | 1000 | 9.55 |
| 10:19 ET | 903 | 9.64 |
| 10:24 ET | 200 | 9.69 |
| 10:28 ET | 2117 | 9.69 |
| 10:30 ET | 3277 | 9.57 |
| 10:32 ET | 648 | 9.638 |
| 10:33 ET | 100 | 9.6 |
| 10:35 ET | 15675 | 9.69 |
| 10:37 ET | 900 | 9.69 |
| 10:39 ET | 1700 | 9.65 |
| 10:42 ET | 300 | 9.655 |
| 10:44 ET | 100 | 9.645 |
| 10:46 ET | 200 | 9.55 |
| 10:48 ET | 100 | 9.6 |
| 10:50 ET | 1139 | 9.52 |
| 10:51 ET | 100 | 9.68 |
| 10:53 ET | 200 | 9.54 |
| 10:55 ET | 4272 | 9.67 |
| 10:57 ET | 377 | 9.53 |
| 11:00 ET | 200 | 9.59 |
| 11:02 ET | 3000 | 9.585 |
| 11:04 ET | 2584 | 9.585 |
| 11:06 ET | 1420 | 9.57 |
| 11:08 ET | 799 | 9.56 |
| 11:09 ET | 500 | 9.555 |
| 11:11 ET | 535 | 9.58 |
| 11:13 ET | 2823 | 9.81 |
| 11:15 ET | 500 | 9.55 |
| 11:18 ET | 100 | 9.645 |
| 11:20 ET | 200 | 9.56 |
| 11:22 ET | 100 | 9.71 |
| 11:24 ET | 200 | 9.56 |
| 11:26 ET | 3731 | 9.57 |
| 11:27 ET | 100 | 9.565 |
| 11:29 ET | 3900 | 9.66 |
| 11:31 ET | 1740 | 9.52 |
| 11:38 ET | 1400 | 9.7 |
| 11:42 ET | 500 | 9.845 |
| 11:45 ET | 100 | 9.84 |
| 11:47 ET | 300 | 9.64 |
| 11:49 ET | 3410 | 9.785 |
| 11:51 ET | 100 | 9.76 |
| 11:54 ET | 1078 | 9.84 |
| 12:00 ET | 2000 | 9.795 |
| 12:02 ET | 200 | 9.85 |
| 12:03 ET | 100 | 9.845 |
| 12:05 ET | 400 | 9.86 |
| 12:07 ET | 100 | 9.895 |
| 12:09 ET | 100 | 9.895 |
| 12:12 ET | 300 | 9.89 |
| 12:14 ET | 100 | 9.89 |
| 12:18 ET | 100 | 9.885 |
| 12:20 ET | 600 | 9.85 |
| 12:23 ET | 100 | 9.87 |
| 12:25 ET | 340 | 9.82 |
| 12:30 ET | 100 | 9.87 |
| 12:32 ET | 100 | 9.805 |
| 12:34 ET | 1103 | 9.91 |
| 12:36 ET | 400 | 9.86 |
| 12:43 ET | 900 | 9.9 |
| 12:45 ET | 5894 | 10.1 |
| 12:48 ET | 200 | 10.0799 |
| 12:50 ET | 1200 | 9.95 |
| 12:52 ET | 2046 | 10.19 |
| 12:54 ET | 207 | 10.075 |
| 12:56 ET | 300 | 10.1 |
| 12:57 ET | 500 | 10.17 |
| 12:59 ET | 200 | 10.13 |
| 01:03 ET | 2035 | 10.05 |
| 01:06 ET | 453 | 10.06 |
| 01:12 ET | 200 | 9.98 |
| 01:14 ET | 200 | 10.08 |
| 01:15 ET | 500 | 9.98 |
| 01:19 ET | 1200 | 10.14 |
| 01:24 ET | 200 | 10.07 |
| 01:26 ET | 1000 | 10.13 |
| 01:35 ET | 3221 | 10 |
| 01:37 ET | 800 | 10.06 |
| 01:39 ET | 100 | 10.015 |
| 01:44 ET | 1634 | 10.01 |
| 01:46 ET | 1380 | 9.88 |
| 01:50 ET | 100 | 9.87 |
| 01:55 ET | 900 | 9.985 |
| 01:57 ET | 115 | 9.86 |
| 02:00 ET | 2700 | 10.13 |
| 02:02 ET | 2300 | 9.94 |
| 02:09 ET | 100 | 10 |
| 02:18 ET | 2100 | 9.995 |
| 02:20 ET | 1000 | 9.97 |
| 02:22 ET | 500 | 10 |
| 02:24 ET | 100 | 10.01 |
| 02:26 ET | 100 | 10.02 |
| 02:27 ET | 1300 | 10 |
| 02:29 ET | 1130 | 9.89 |
| 02:31 ET | 100 | 10.13 |
| 02:33 ET | 9788 | 10 |
| 02:36 ET | 1260 | 10 |
| 02:38 ET | 300 | 10.135 |
| 02:40 ET | 100 | 10 |
| 02:44 ET | 400 | 10.085 |
| 02:45 ET | 500 | 10.09 |
| 02:47 ET | 5583 | 9.995 |
| 02:49 ET | 100 | 9.97 |
| 02:51 ET | 3611 | 9.87 |
| 02:54 ET | 117 | 9.87 |
| 02:56 ET | 2425 | 9.91 |
| 02:58 ET | 200 | 9.96 |
| 03:00 ET | 400 | 9.9695 |
| 03:02 ET | 800 | 9.87 |
| 03:03 ET | 200 | 9.89 |
| 03:05 ET | 100 | 9.895 |
| 03:07 ET | 2543 | 9.67 |
| 03:09 ET | 200 | 9.8 |
| 03:12 ET | 560 | 9.75 |
| 03:14 ET | 1500 | 9.81 |
| 03:16 ET | 1880 | 9.795 |
| 03:21 ET | 3481 | 9.81 |
| 03:23 ET | 6613 | 9.78 |
| 03:25 ET | 1909 | 9.845 |
| 03:30 ET | 1600 | 9.96 |
| 03:32 ET | 100 | 9.97 |
| 03:34 ET | 3500 | 9.78 |
| 03:36 ET | 1200 | 9.79 |
| 03:38 ET | 1900 | 9.77 |
| 03:41 ET | 100 | 9.65 |
| 03:43 ET | 1000 | 9.785 |
| 03:45 ET | 5798 | 9.72 |
| 03:48 ET | 300 | 9.75 |
| 03:50 ET | 3312 | 9.75 |
| 03:52 ET | 4274 | 9.79 |
| 03:54 ET | 4493 | 9.68 |
| 03:56 ET | 4237 | 9.77 |
| 03:57 ET | 4352 | 9.8 |
| 03:59 ET | 10899 | 9.82 |
Apr 16, 2024
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316, from 8:01PM ET on Tuesday Apr 16, 2024 by Dow Jones
8:01PM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 10, 2024
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368, from 8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
DJ Acrivon Therapeutics Shares Rise 59% After Private Placement Financing, from 7:28AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:28AM ET on Tuesday Apr 09, 2024 by Dow JonesAcrivon Therapeutics Announces $130 Million Private Placement Financing, from 7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 09, 2024 by Dow JonesPress Release: Acrivon Therapeutics Announces $130 Million Private Placement Financing, from 7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acrivon Therapeutics Inc | 293.6M | -3.6x | --- |
Nanobiotix SA | 270.2M | -3.2x | --- |
Anavex Life Sciences Corp | 302.2M | -6.9x | --- |
Q32 Bio Inc | 296.1M | -0.7x | --- |
Nautilus Biotechnology Inc | 302.7M | -4.9x | --- |
Ventyx Biosciences Inc | 302.8M | -1.3x | --- |
Company Information
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Contact Information
- Headquarters
- 480 Arsenal Way, Suite 100WATERTOWN, MA, United States 02472
- Phone
- 617-207-8979
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Peter Blume-Jensen
- Chief Financial Officer
- Rasmus Holm-Jorgensen
- Chief Operating Officer
- Eric Devroe
- Executive Vice President - Business Operations, Director
- Kristina Masson
- Chief Medical Officer
- Erick Gamelin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $293.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.73 |
Book Value | $5.38 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
